marketinference20h
SMMT Gains Today, Yet Still Below 52-Week Peak
Pharmaceutical company Summit Therapeutics is standing out today, surging to $20.45 and marking a 10.6% change. In comparison ...
Hosted on MSN20h
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation
Fintel reports that on February 28, 2025, Goldman Sachs initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy ...
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Piper Sandler analyst Yasmeen Rahimi initiated coverage on Avalo Therapeutics, Inc. AVTX with an Overweight rating and ...